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Triple-Targeting Gram-Negative Selective antimicrobial peptides 
capable of Disrupting the Cell Membrane and Lipid A Biosynthesis 
T. M. Postmaa and R. M. J. Liskampa*  
Early lipid A biosynthesis is a potential antimicrobial target as this 
is an essential component of lipid A producing Gram-negative 
bacteria. Herein, we introduce a potent and highly synergistic 
Gram-negative selective triple-targeting antimicrobial peptide. 
The peptide contains a dual lipid A biosynthesis inhibiting 
sequence and an antimicrobial sequence. 
Decades of abundant and often overprescribed use of 
antibiotics has marked a steep global rise in multidrug-
resistant bacteria.1 Especially the emergence of multidrug-
resistant Gram-negative (MRGN) bacteria in healthcare 
settings poses a serious threat to public health.2 In the United 
States more than 2 million persons are infected annually with 
antibiotic resistant bacteria.3 In Europe, a significant increase 
in resistance in MRGN bacteria, including resistance to last-line 
antibiotics such as carbapenems and polymyxins, was 
observed over the last few years according to the annual 
surveillance report of the European Centre for Disease 
Prevention and Control.4 Resistance to last-line antibiotics 
clearly illustrates the severity of the problem, where last-line 
antibiotics are typically only used as emergency treatment 
when other antibiotics fail. Furthermore, there are few 
antibiotics and fewer new antibiotic classes in the 
pharmaceutical pipelines which exacerbates the public health 
risk to MRGN bacteria. There is an urgent need to discover 
antimicrobial agents with novel mechanisms of action to 
address these serious threats to human health and well-being. 
 Targeting the early lipid A biosynthesis in Gram-negative 
bacteria has been proposed as a viable antimicrobial strategy 
with lipid A being essential to bacterial survival in lipid A 
producing Gram-negative bacteria.5 Lipid A is the membrane-
anchor of lipopolysaccharide, which constitutes the outer layer 
of the Gram-negative bacterial membrane and is responsible 
for the endotoxic effects observed in numerous Gram-negative 
infections. The early biosynthesis of lipid A is characterized by 
a series of catalytic acetyltransferases that add lipid chains to a 
molecule of UDP-N-acetylglucosamine (Scheme 1). The critical 
steps in early lipid A biosynthesis are performed by UDP-N-
acetylglucosamine acetyltransferase (LpxA) and UDP-3-O-(R-3-
hydroxyacyl)GlcN N-acetyltransferase (LpxD).  
 Recently, from a phage display library against both LpxA 
and LpxD the peptide RJPXD33, a dual targeting 12-residue 
peptide (TNLYMLPKWDIP) has been identified with inhibition 
constants (IC50) of 19 µM and 3.5 µM respectively.6 The 
bioactivity of this RJPXD33 peptide was determined by 
inducing a transfected plasmid coding for the peptide in E. coli, 
which led to inhibition of bacterial growth. These results 
indicate that LpxA and LpxD are essential enzymes for the 
survival of lipid A producing bacteria. Thus, the RJPXD33 
peptide offers a promising sequence for the design of multi-
targeting Gram-negative selective antimicrobial agents. 
Targeting several essential targets inside bacteria may reduce 
the emergence of resistance against these potential multi-
targeting  antibiotics since several mutations in critical targets 
will be required to cause resistance.7  
 The significant inhibitory activity of LpxA and LpxD by the 
RJPXD33 sequence shows promise for attacking Gram-negative 
bacteria. However, this dual-targeting peptide sequence lacks 
the typical characteristics of a cell penetrating peptide, which 
decreases the likelihood of this peptide to reach the target 
intracellular acetyltransferases LpxA and LpxD. To enable cell 
entry and subsequent inhibition of these transferases, 
conjugation of the RJPXD33 peptide to a cell penetrating 
peptide sequence was required. Furthermore, by using a cell 
penetrating sequence that displays potent antimicrobial 
activity a certain degree of synergy with the RJPXD33 sequence 
was expected. Thus, we envisioned a "triple-targeting" Gram-
negative selective antimicrobial peptide by designing a cell 
penetrating antimicrobial peptide RJPXD33 conjugate. The 
RJPXD33 sequence targets the two acetyltransferases LpxA 
and LpxD, and the cell penetrating peptide increases the  
permeability of the bacterial membrane acting as both shuttle  
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Scheme 1: Lipid A biosynthesis in E. coli6   
and disruptor of bacterial membrane integrity.  
 There is significant similarity between cell penetrating and 
antimicrobial peptides, however not all cell penetrating 
peptides are antimicrobial. The exact difference is poorly 
understood as there is frequently a strong sequence overlap, 
for instance with respect to the presences of several cationic 
residues.8 Cationic peptides have a strong tendency to interact 
with the negative bacterial membrane. There are several 
mechanisms through which antimicrobial peptides act, most of 
which primarily damage the bacterial membrane.9 In the 
design of a triple-targeting peptide the antimicrobial sequence 
required a fine balance between antimicrobial activity and 
ability to shuttle cargo into bacterial cells to ensure synergistic 
activity on the bacterial membrane and disruption of early lipid 
A biosynthesis by inhibiting LpxA and LpxD. The cationic 
bactericidal peptide KFFKFFKFF had shown to significantly 
increase the permeability of bacterial membranes which 
resulted in signification potentiation of the antimicrobial 
effects of several antibiotics in solution.10 A similar peptide 
sequence, KFFKFFKFFK, was used in a peptide nucleic acid 
(PNA) conjugate that demonstrated a significant increase in 
uptake and potency of a PNA construct.11 Therefore, we chose 
the peptide sequence KFFKFFKFFK for the triple-targeting 
conjugate. To determine suitable placement of the 
KFFKFFKFFK sequence at the N- or C-terminus of the RJPXD33 
sequence the crystal structure of a RJPXD33 LpxA trimer 
complex was examined.12 The peptide was bound vertically 
into a pocket formed in the middle of the LpxA homotrimer 
allowing sufficient space to fit the N-terminus with the cationic 
sequence. A glycine spacer was inserted in between to give the 
complete conjugate sequence KFFKFFKFFKGTNLYMLPKWDIP. 
 The following peptides were prepared using Fmoc solid-
phase peptide synthesis: H-GTNLYMLPKWDIP-NH2 (1), H-
KFFKFFKFFK-NH2 (2) and H-KFFKFFKFFKGTNLYMLPKWDIP-NH2 
(3). The antibacterial activity of peptides 1-3 was evaluated in 
a broth microdilution assay to determine the minimum 
inhibitory concentration (MIC), defined as the lowest 
concentration of a compound that will visibly inhibit bacterial 
growth. Prior to determining the MIC values of peptides 1-3 
we had to choose relevant Gram-negative bacteria. The 
RJPXD33 peptide was discovered using LpxA and LpxD from E. 
coli, which renders E. coli an obvious choice. Moreover, multi-
drug resistant E. coli, including carbapenem resistance, is 
spreading rapidly and is a common human pathogen that 
causes community and nosocomial acquired infections.13 E. 
coli together with Klebsiella pneumoniae, Acinetobacter 
baumannii  and Pseudomonas aeruginosa are part of the high 
priority ESKAPE pathogens and were included in the MIC 
testing.14 The MRGNB Citrobacter freundii, a common 
nosocomial cause of infection, can be extremely drug-
resistant. The final two bacteria that we chose to test our 
conjugates against have a rising incidence of resistance, were 
Shigella sonnei and Salmonella enterica.15  As a control we 
used the Gram-positive bacteria, Staphylococcus aureus and S. 
epidermidis, which do not express the LpxA and LpxD 
acetyltransferases. The MICs of these bacteria were 
determined using an established protocol within our group 
with some minor modifications (Table 1).16 
 The MIC values confirmed our initial expectation that 
extracellular dual-targeting peptide 1 would prove to be 
inactive. Peptide 1 caused no inhibition of bacterial growth in 
all bacterial species tested at high concentration (1mg/mL, 563 
µM). In contrast, antimicrobial peptide 2 demonstrated potent 
inhibition of growth in all bacteria. An inhibitory range 
between 1 and 32 µM for the Gram-negative bacteria, and 
between 0.5 and 16 µM for Gram-positive S. epidermidis and S. 
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aureus was found. A combination of peptide 1 and 2 gave the 
same MIC values as for peptide 2 alone. The triple-targeting 
peptide construct 3 demonstrated very potent synergistic 
inhibition of growth in all Gram-negative bacteria tested < 2 
µM. This is a significant increase in potency over peptide 2 
with a 1 – 128 fold decrease of the MIC values. In K. 
pneumoniae the increase in potency was most pronounced 
with a 128 fold decrease of MIC value from 126 µM to 0.25 
 
 
Table 1: Evaluation of antibacterial activity of peptides using a broth microdilution assay 
 
Bacterium 
 
Gram 
 
Dual (1) 
MIC (µM) 
 
AMP (2) 
MIC (µM) 
 
Dual (1) + AMP (2) 
MIC (µM) 
 
Triple (3) 
MIC (µM) 
Escherichia coli - >563 8 8 0.5 
Klebsiella pneumoniae - >563 32 32 0.25 
Citrobacter freundii - >563 4 4 0.5 
Shigella sonnei - >563 2 2 0.25 
Salmonella enterica - >563 16 16 2 
Pseudomonas aeruginosa - >563 1 1 1 
Acinetobacter baumannii - >563 32 32 0.25 
Staphylococcus aureus + >563 16 16 32 
Staphylococcus epidermidis + >563 0.5 0.5 1 
 
µM. In contrast, the only exception with the Gram-negative 
bacteria was P. aeruginosa in which no increase in potency 
was observed. Conversely, the effect of peptide 3 on Gram-
positive bacteria was reversed by a 2 fold increase in the MIC 
values. This increase in MIC-value was expected as Gram-
positive bacteria do not express the LpxA and LpxD 
acetyltransferases. Thus, the antimicrobial activity of peptide 3 
in Gram-positive bacteria is probably primarily due to the 
membrane damaging cationic KFFKFFKFFK sequence.  
 Lipopolysaccharide deficient, polymyxin E resistant A. 
baumannii strains with mutations in either LpxA or LpxD, 
resulting in inactivation of lipid A biosynthesis and loss of 
lipopolysaccharide, have been reported.17,18 The strain AL1851 
ΔLpxA contains a 445-bp deletion in LpxA, and the strain 
AL1851 ΔLpxD contains a single base deletion at nucleotide 
364 in LpxD. The peptide MIC values were determined for 
three A. baumannii strains to study the effects of the triple-
targeting peptide 3 (Table 2).  
 The results show the same synergistic increase in potency 
for the parent A. baumannii as for the LpxA/D mutated strains.  
The polymyxin E MIC values have increased significantly for the 
Lpx mutants, which is caused by loss of lipopolysaccharide. 
Polymyxin E binds to lipopolysaccharide and this explains the 
increase in MIC in the Lpx mutants. Loss of the 
lipopolysaccharide protective barrier greatly increased the 
potency of ampicillin in the Lpx mutants. This highlights a 
potentially interesting application of the triple-targeting 
conjugate on Gram-negative bacteria. In addition to its action 
it may sensitize bacteria to other antibiotics by inhibiting 
lipopolysaccharide biosynthesis. However, the increase in 
potency with triple-targeting peptide 3 in Lpx mutants was 
unexpected. Especially, when considering that resistance to 
last-line antibiotics such as polymyxin E is a serious clinical 
issue, the preservation of potent activity against Lpx mutants 
of triple-targeting peptide 3 is very interesting. The absence of 
LPS will significantly impact the membrane integrity of Gram-
negative bacteria and increase permeability.17 Therefore, 
peptide 3 may retain increased activity due to interaction of 
the hydrophobic dual-targeting sequence with the 
hydrophobic membrane environment. This also raises the 
possibility of additional targets within the cell and 
Table 2: MIC determination in A. baumannii strains 
 
Bacterium 
 
AMP (2) 
(µM) 
 
Dual (1) + AMP (2) 
 (µM) 
 
Triple (3)  
(µM) 
 
Polymyxin E 
(µM) 
 
Ampicillin 
(µM) 
A. baumannii (ATCC 19606) 32 32 0.25 0.4 337 
A. baumannii (AL1851 – ΔLpxA) 16 16 0.25 3 3 
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A. baumannii (Al1852 – ΔLpxD) 32 32 0.25 >400 3 
 
 
Table 3: Haemolysis of sheep erythrocytes 
 
 
Compound 
 
Percentage haemolysis at 
64 µM  
Peptide 2 0.2 ± 0.03 
Peptide 3 0.7 ± 0.2 
1% Triton X-100 100 ± 0.1  
 
warrants further study of this type of multi-targeting peptide. 
 The MIC determination of triple-targeting peptide 3 
demonstrated very potent and selective inhibition of growth in 
Gram-negative bacteria. Triple-targeting peptides show 
significant promise for application in Gram-negative bacteria 
with emerging antibiotic resistance. However, cationic 
peptides that have antimicrobial activity may act as strong 
cationic detergents.19 The detergent-like properties of such 
cationic peptides can lead to strong cytotoxicity, which is 
unacceptable in any in vivo animal or human applications. 
Therefore, the cytotoxicity of peptides 2 and 3 was determined 
in a haemolysis assay using sheep erythrocytes.20 In this assay 
the extent of haemolysis was determined by measuring the 
concentration of released haemoglobin into solution 
compared to 100% haemolysis (1% Triton X-100) after 1h at 37 
°C. The percentage of haemolysis at 64 µM is presented as this 
is at least 10 times higher than the MIC concentrations for 
peptide 3 in Gram-negative bacteria (Table 3).   
 Haemolysis was determined in a concentration range of 
0.065 – 128 µM for peptides 2 and 3. The percentage of 
haemolysis for peptide 2 at 64 µM was less than 1% compared 
to 100% haemolysis with Triton X-100. With peptide 3, 
haemolysis at 64 µM was less than 1% as well. Peptides 2 and 
3 showed very low haemolysis, especially given that the MICs 
against Gram-negative bacteria for peptide 3 are below 5 µM. 
Less than 1% haemolysis was observed at 14 to 128 times the 
MIC concentrations. These results clearly demonstrate that 
peptide 3 had a very low level of haemolysis with no 
haemolysis observed at the required active antimicrobial 
concentrations.  
Conclusions 
A Gram-negative selective triple-targeting antimicrobial 
peptide conjugate (3), based on a lipopolysaccharide 
biosynthesis inhibiting sequence and an antimicrobial peptide, 
was prepared and evaluated for biological activity and 
cytotoxic properties. For comparison, the LpxA and LpxD 
targeting peptide (1) as well as the antimicrobial cell 
penetrating peptide (2) were prepared and evaluated. Peptide 
1 showed no inhibition of bacterial growth at high 
concentration. Potent antimicrobial activity was observed with 
peptide 2. A mixture of peptide 1 and 2 did not increase 
potency. Triple targeting peptide 3 demonstrated very potent 
synergistic antimicrobial effects in Gram-negative bacteria, 
with MIC values below 2 µM, corresponding to a 2 – 128 fold 
decrease in MIC compared to antimicrobial peptide 2. Towards 
Gram-positive bacteria the MIC values of peptide 3 were 
increased because these bacteria do not express 
acetyltransferase enzymes LpxA and LpxD. Peptide 3 showed 
and unexpected increase in potency with lipopolysaccharide 
deficient Lpx mutants and may indicate additional targets. The 
cytotoxicity of triple-targeting peptide 3 was found to be very 
low in a haemolytic assay. Overall, this work demonstrates 
that peptide 3 shows a significant synergistic increase in 
potency compared to the individual peptides 1 and 2. This 
highly promising multi-targeting strategy will be further 
studied in our subsequent work. The intracellular binding of 
peptide 3 to LpxA and LpxD will be studied to confirm the 
exact mechanism of antimicrobial action. By employing multi-
targeting antimicrobial peptides, we envision the possibility of 
decreasing the emergence of new resistance mechanisms. 
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